ABSTRACT
Diffuse large B-cell non-Hodgkin's lymphoma (LDCGB) is one of the best examples of chemotherapy curable malignant diseases. This "Oncoguía SEOM" summarizes the basic directions of staging and recommended treatment options. The staging study should be thorough and includes clinical, laboratory, diagnostic imaging and nuclear medicine. Treatment depends on patient characteristics and comorbidity and on disease extension and prognostic factors. In localized cases, chemoimmunotherapy (CHOP-R) of short duration, followed by involved-field irradiation is the preferred option. In advanced stages, the association of CHOP-like chemotherapy and Rituximab has been a major breakthrough in terms of cure rate. It is important do not forget the supportive treatment in these patients (AU)
Subject(s)
Humans , Male , Female , Lymphoma, Large B-Cell, Diffuse/epidemiology , Lymphoma, Large B-Cell, Diffuse/therapy , Medical Oncology/methods , Medical Oncology/standards , Medical Oncology/trends , Practice Guidelines as Topic , Algorithms , Societies, Medical/organization & administration , Societies, Medical/standards , Societies, Medical , Spain/epidemiologyABSTRACT
An 80-year-old man was admitted to hospital with low-grade fever, weight loss, asthenia and anorexia. Physical examination revealed generalised ichthyosis with palmoplantar hyperkeratosis. CT scan showed retroperitoneal and inguinal lymph node enlargement. An inguinal lymph node biopsy revealed Hodgkin's disease (nodular-sclerosing subtype). The patient received chemotherapy, showing a clear improvement of both skin lesions and lymph nodes (AU)
Subject(s)
Humans , Male , Aged, 80 and over , Hodgkin Disease/diagnosis , Hodgkin Disease/drug therapy , Ichthyosis/diagnosis , Paraneoplastic Syndromes/diagnosis , Paraneoplastic Syndromes/drug therapy , Hodgkin Disease/pathology , Ichthyosis/pathology , Lymph Nodes/pathology , Paraneoplastic Syndromes/pathologyABSTRACT
Primary ovarian Burkitt lymphoma (BL) is a rare neoplasm in adults. We report a 30-year-old woman diagnosed with primary bilateral ovarian BL. She presented features of a twisted ovarian cyst and underwent bilateral salpingo-oophorectomy. The histopathologic evaluation yielded the diagnosis of BL and subsequently she received chemoimmunotherapy with CODOX-M-IVAC plus rituximab (anti-CD20 monoclonal antibody) (AU)
No disponible
Subject(s)
Humans , Female , Adult , Antibodies, Monoclonal/therapeutic use , Burkitt Lymphoma/diagnosis , Burkitt Lymphoma/drug therapy , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/drug therapy , Antibodies, Monoclonal, Murine-Derived , Antibiotics, Antineoplastic/therapeutic useABSTRACT
INTRODUCTION: Multiple myeloma (MM) is a plasm-cell neoplasm, that is characterized by a monoclonal protein in the serum or urine. Bortezomib is an efficacy drug for the second line treatment of MM. PATIENTS AND METHOD: We conducted a retrospective study of 21 consecutive cases with refractory MM treated with bortezomib and dexamethasone as second line therapy, with the objective of analyzing the overall response rate (primary end point), the progression-free survival (PFS), the overall survival (OS), the duration of response (DR) and toxicity profile (second end points). RESULTS: In our study we found an overall response rate of 70%. With a median follow-up of 15 months, we had a median PFS of 12 months (95% CI: 2-21 months), with a median OS of 17 months (95% CI: 2-32 months), and a median DR of 9 months (95% CI: 5-13 months). Fourty-seven percent of patients had neuropathy, the 33% thrombocytopenia, 13.33% anemia and 26.66% diarrhea. CONCLUSIONS: The combination of bortezomib and dexamethasone is an effective and safe treatment in second line of refractory MM, with a manageable toxicity.
Subject(s)
Antineoplastic Agents/therapeutic use , Boronic Acids/therapeutic use , Dexamethasone/therapeutic use , Multiple Myeloma/drug therapy , Pyrazines/therapeutic use , Adult , Aged , Aged, 80 and over , Bortezomib , Female , Humans , Male , Middle Aged , Multiple Myeloma/mortality , Recurrence , Retrospective Studies , Survival RateABSTRACT
Introducción: El mieloma múltiple (MM) es una neoplasia de células plasmáticas, que se caracteriza por la presencia de una proteína monoclonal en suero u orina. Bortezomib es un fármaco eficaz en el tratamiento de segunda línea del MM. Pacientes y métodos: Hemos realizado un estudio retrospectivo de una serie de 21 casos consecutivos de MM refractario a los que hemos tratado con bortezomib y dexametasona en segundas líneas, con el objetivo de analizar la tasa de respuesta (objetivo primario), la supervivencia libre de progresión (SLP), la supervivencia global (SG), la duración de respuesta (DR) y la toxicidad (objetivos secundarios). Resultados: En nuestro estudio hemos encontrado una tasa de respuesta total de 70%. Con una mediana de seguimiento de 15 meses, hemos obtenido una mediana de SLP de 12 meses (IC95%: 2-21 meses), una mediana de SG de 17 meses (IC95%:2-32 meses) y una mediana de DR de 9 meses (IC95%: 5-13 meses). El 47 % de los pacientes presentaron neuropatía,el 33% trombocitopenia, 13,33% anemia, y 26,66% diarrea. Conclusiones: La combinación de bortezomib y dexametasona es un tratamiento efectivo y seguro en segundas líneas de MM refractario, con una toxicidad manejable
Introduction: Multiple myeloma (MM) is a plasm-cell neoplasm, thatis characterized by a monoclonal protein in the serum or urine. Bortezomib is an efficacy drug for the second line treatment of MM. Patients and method: We conducted a retrospective study of 21 consecutive cases with refractory MM treated with bortezomib and dexamethasone as second line therapy, with the objective of analyzing the overall response rate (primary end point), the progression-free survival (PFS), the overall survival (OS), the duration of response (DR) and toxicity profile (second end points). Results: In our study we found an overall response rate of 70%. With a median follow-up of 15 months, we had a median PFS of 12 months (95% CI: 2-21 months), with a median OS of 17 months (95% CI: 2-32 months), and a median DR of 9 months (95% CI: 5-13 months). Fourtyseven percent of patients had neuropathy, the 33% thrombocytopenia,13.33% anemia and 26.66% diarrhea. Conclusions: The combination of bortezomib and dexamethasone is an effective and safe treatment in second line of refractory MM, with amanageable toxicity
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Dexamethasone/therapeutic use , Multiple Myeloma/diagnosis , Multiple Myeloma/drug therapy , Antineoplastic Agents/therapeutic use , Boronic Acids/therapeutic use , Retrospective Studies , Hereditary Sensory and Autonomic Neuropathies/complications , Bone Marrow/pathologyABSTRACT
Primary effusion lymphoma is a rare high-grade B-cell non-Hodgkin's lymphoma associated with human herpesvirus 8 (HHV-8) infection, and is mostly observed in the course of HIV infection (AIDS). The prognosis is poor, with reported median survival time shorter than 6 months. We present a case of a 65-year-old man, with prior unknown origin chronic hepatopathy, chronic hemolytic anaemia, and ascites. Biopsy of peritoneum showed a primary effusion lymphoma. The patient died two months later.
Subject(s)
Ascitic Fluid/pathology , Lymphoma/diagnosis , Aged , Anemia, Hemolytic/complications , Fatal Outcome , Humans , Liver Cirrhosis/complications , MaleABSTRACT
El linfoma primario de cavidades es un linfoma no Hodgkin de fenotipo B raro, de alto grado, asociado con el virus herpes humano 8 (VHH-8), y la mayoría de los casos se dan en el seno de una infección por VIH (SIDA). El pronóstico es pobre, con una mediana de supervivencia menor a los 6 meses. Presentamos el caso de un varón de 65 años, con una hepatopatía crónica de origen incierto, anemia hemolítica crónica y ascitis. La biopsia del peritoneo evidenció un linfoma primario de cavidades. El paciente falleció dos meses después
Primary effusion lymphoma is a rare high-grade B-cell non-Hodgkin's lymphoma associated with human herpesvirus 8 (HHV-8) infection, and is mostly observed in the course of HIV infection (AIDS). The prognosis is poor, with reported median survival time shorter than 6 months. We present a case of a 65-year-old man, with prior unknown origin chronic hepatopathy, chronic hemolytic anaemia, and ascitis. El biopsy of peritoneum showed a primary effusion lymphoma. The patient died two month later